No grapefruit list grows
November 30, 2012
THE list of medications which do
not mix well with the humble
grapefruit has grown, according to
a new study published in the
Canadian Medical Association
Journal.
The research, undertaken by
David Bailey, a clinical
pharmacologist at the Lawson
Health Research Institute in
London, Ontario, who alerted the
world to grapefruit interactions
over 20 years ago, reviewed current
evidence regarding grapefruit and
medications and found that the list
of no-go grapefruit drugs has
grown from 17 to 44.
“What I've noticed over the last
four years is really quite a
disturbing trend, and that is the
increase in the number of drugs
that can produce not only adverse
reactions but extraordinarily
serious adverse drug reactions,”
Bailey said.
The expanded list includes: anticancer
drugs; Crizotinib, Dasatinib,
Erlotinib, Everolimus, Lapatinib,
Nilotinib, Pazopanib, Sunitinib,
Vandetanib, and Venurafenib; as
well as anti-infective drugs;
Erythromycin, Halofantrine,
Maraviroc, Primaquine, Quinine,
and Rilpivirine.
The list also includes cholestarol
lowering drugs: Atorvastatin,
Lovastatin, Simvastatin;
cardiovascular medications:
Amiodarone, Apixaban,
Clopidogrel, Dronedarone,
Eplerenone, Felodipine,
Nifedipine, Quinidine, Rivaroxaban
and Ticagrelor; as well as central
nervous system meds: Alfentanil
(oral), Buspirone,
Dextromethorphan, Fentanyl (oral),
Ketamine (oral), Lurasidone,
Oxycodone, Pimozide, Quetiapine,
Triazolam, and Ziprasidone.
Other drugs on the list include:
gastrointestinal medication
Domperidone; immunosuppressants
Cyclosporine, Everolimus, Sirolimus,
and Tacrolimus; and uriary tract
drugs Darifenacin, Fesoterodine,
Solifenacin, Silodosin, and
Tamsulosin.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Nov 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Nov 12
